Pfizer and Innovent Biologics Announce $10.5 Billion Collaboration to Develop Cancer Therapies
Pharmaceutical giant Pfizer has entered a global licensing agreement with China's Innovent Biologics, valued at up to $10.5 billion, to develop next-generation cancer therapies including antibody-drug conjugates and multi-specific antibodies. The deal includes an upfront payment of $650 million for Innovent, along with potential milestone payments totaling up to $9.85 billion.
Tickers: $PFE
Topics: Cancer Therapies Global Licensing Agreement Pharmaceuticals